"Antipsychotic Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Agents that control agitated psychotic behavior, alleviate acute psychotic states, reduce psychotic symptoms, and exert a quieting effect. They are used in SCHIZOPHRENIA; senile dementia; transient psychosis following surgery; or MYOCARDIAL INFARCTION; etc. These drugs are often referred to as neuroleptics alluding to the tendency to produce neurological side effects, but not all antipsychotics are likely to produce such effects. Many of these drugs may also be effective against nausea, emesis, and pruritus.
| Descriptor ID |
D014150
|
| MeSH Number(s) |
D27.505.696.277.950.040 D27.505.954.427.210.950.040 D27.505.954.427.700.872.331
|
| Concept/Terms |
Antipsychotic Agents- Antipsychotic Agents
- Agents, Antipsychotic
- Antipsychotics
- Major Tranquilizers
- Tranquilizers, Major
- Tranquillizing Agents, Major
- Agents, Major Tranquillizing
- Major Tranquillizing Agents
- Neuroleptic Drugs
- Drugs, Neuroleptic
- Neuroleptics
- Tranquilizing Agents, Major
- Agents, Major Tranquilizing
- Major Tranquilizing Agents
- Antipsychotic Drugs
- Drugs, Antipsychotic
- Neuroleptic Agents
- Agents, Neuroleptic
Antipsychotic Effect- Antipsychotic Effect
- Effect, Antipsychotic
- Antipsychotic Effects
- Effects, Antipsychotic
|
Below are MeSH descriptors whose meaning is more general than "Antipsychotic Agents".
Below are MeSH descriptors whose meaning is more specific than "Antipsychotic Agents".
This graph shows the total number of publications written about "Antipsychotic Agents" by people in this website by year, and whether "Antipsychotic Agents" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 4 | 1 | 5 |
| 1997 | 2 | 1 | 3 |
| 1998 | 1 | 2 | 3 |
| 1999 | 1 | 0 | 1 |
| 2000 | 1 | 3 | 4 |
| 2001 | 6 | 2 | 8 |
| 2002 | 1 | 1 | 2 |
| 2003 | 1 | 1 | 2 |
| 2004 | 5 | 1 | 6 |
| 2005 | 6 | 4 | 10 |
| 2006 | 2 | 1 | 3 |
| 2007 | 4 | 1 | 5 |
| 2008 | 5 | 1 | 6 |
| 2009 | 8 | 0 | 8 |
| 2010 | 3 | 1 | 4 |
| 2011 | 4 | 2 | 6 |
| 2012 | 2 | 3 | 5 |
| 2013 | 5 | 2 | 7 |
| 2014 | 6 | 1 | 7 |
| 2015 | 4 | 1 | 5 |
| 2016 | 7 | 1 | 8 |
| 2017 | 3 | 1 | 4 |
| 2018 | 1 | 0 | 1 |
| 2019 | 4 | 0 | 4 |
| 2020 | 6 | 1 | 7 |
| 2021 | 2 | 0 | 2 |
| 2022 | 3 | 0 | 3 |
| 2023 | 9 | 0 | 9 |
| 2024 | 3 | 1 | 4 |
| 2025 | 4 | 0 | 4 |
| 2026 | 3 | 1 | 4 |
To return to the timeline,
click here.
Below are the most recent publications written about "Antipsychotic Agents" by people in Profiles.
-
Brain-derived extracellular vesicle (BDEV) abundance and BDEV protein associations with clinical phenotypes and treatment response in untreated first-episode psychosis. Brain Behav Immun. 2026 Nov; 138:106912.
-
Moderate to severe negative symptoms predict low risk of symptoms worsening in schizophrenia patients in CATIE. Schizophr Res. 2026 Sep; 295:150-155.
-
Quality of life in early-phase schizophrenia patients starting treatment with long-acting injectable vs. oral antipsychotic drugs: Data from the European Long-acting Antipsychotics in Schizophrenia Trial (EULAST). Eur Psychiatry. 2026 04 21; 69(1):e51.
-
Is it Possible To Identify Patients After Their First Hospitalization for a Psychotic Disorder Who Do Not Use Anti-Psychotics and are Not Later Rehospitalized? Schizophr Bull. 2026 01 16; 52(1).
-
The effect of switching antipsychotics to aripiprazole versus paliperidone on weight/cardiometabolic parameters: 18-month follow-up findings from the European Long-acting Antipsychotics in Schizophrenia Trial (EULAST). Eur Neuropsychopharmacol. 2026 01; 102:49-57.
-
Impact of Long-Acting Injectable Versus Oral Antipsychotic Treatment on All-Cause Discontinuation Risk in People with Early Phase Schizophrenia and Comorbid Substance Use Disorder: A Secondary Analysis of the EULAST Randomized Trial. CNS Drugs. 2026 01; 40(1):99-109.
-
Subjective well-being in early-phase schizophrenia patients using long-acting injectable versus oral antipsychotic drugs: Data from the European Long-acting Antipsychotics in Schizophrenia Trial (EULAST). Eur Psychiatry. 2025 08 19; 68(1):e116.
-
Reutericyclin, a specialized metabolite of Limosilactobacillus reuteri, mitigates risperidone-induced weight gain in mice. Gut Microbes. 2025 12; 17(1):2477819.
-
Network intervention analysis indicates that roluperidone achieves its effect on negative symptoms of schizophrenia by targeting avolition. Eur Neuropsychopharmacol. 2024 10; 87:18-23.
-
Relapse Rates With Paliperidone Palmitate in Adult Patients With Schizophrenia: Results for the 6-Month Formulation From an Open-label Extension Study Compared to Real-World Data for the 1-Month and 3-Month Formulations. Int J Neuropsychopharmacol. 2024 02 01; 27(2).